E-LIB Suche - Ergebnisse für: Golding, John F

1

Treating benign paroxysmal positional vertigo in acute trau..:

Smith, Rebecca M ; Burgess, Caroline ; Beattie, Jenna...
BMJ Neurology Open. 6 (2024) 1 - p. e000598 , 2024

Link: https://doi.org/10.1136/..

2

Measuring the susceptibility to visually induced motion sic..:

Lukacova, Ivana ; Keshavarz, Behrang ; Golding, John F.
Experimental Brain Research. 241 (2023) 5 - p. 1381-1391 , 2023

Link: https://doi.org/10.1007/..

3

An assessment of the effects of neurokinin1 receptor antago..:

Andrews, Paul L. R. ; Golding, John F. ; Sanger, Gareth J.
British Journal of Clinical Pharmacology. 89 (2023) 12 - p. 3468-3490 , 2023

Link: https://doi.org/10.1111/..

4

Motion sickness diagnostic criteria: Consensus Document of ..:

Cha, Yoon-Hee ; Golding, John F. ; Keshavarz, Behrang...
Journal of Vestibular Research. 31 (2021) 5 - p. 327-344 , 2021

Link: https://doi.org/10.3233/..

5

Smaller Cortisol Awakening Responses Are Associated with Gr..:

Smyth, Nina ; Milani, Monica ; Thorn, Lisa...
Healthcare. 9 (2021) 6 - p. 723 , 2021

Link: https://doi.org/10.3390/..

6

Predicting Individual Susceptibility to Visually Induced Mo..:

Golding, John F. ; Rafiq, Aisha ; Keshavarz, Behrang
Frontiers in Virtual Reality. 2 (2021) - p. , 2021

Link: https://doi.org/10.3389/..

7

The Visually Induced Motion Sickness Susceptibility Questio..:

Keshavarz, Behrang ; Murovec, Brandy ; Mohanathas, Niroshica.
Human Factors: The Journal of the Human Factors and Ergonomics Society. 65 (2021) 1 - p. 107-124 , 2021

Link: https://doi.org/10.1177/..

8

Introducing the VIMSSQ: Measuring susceptibility to visuall..:

Keshavarz, Behrang ; Saryazdi, Raheleh ; Campos, Jennifer L..
Proceedings of the Human Factors and Ergonomics Society Annual Meeting. 63 (2019) 1 - p. 2267-2271 , 2019

Link: https://doi.org/10.1177/..

9

Abnormal visuo-vestibular interactions in vestibular migrai..:

Bednarczuk, Nadja F ; Bonsu, Angela ; Ortega, Marta Casanovas...
Brain. 142 (2019) 3 - p. 606-616 , 2019

Link: https://doi.org/10.1093/..

10

The effects of the selective muscarinic M3 receptor antagon..:

Golding, John F. ; Wesnes, Keith A. ; Leaker, Brian R.
British Journal of Clinical Pharmacology. 84 (2018) 7 - p. 1535-1543 , 2018

Link: https://doi.org/10.1111/..

11

Reliability of functional outcome measures in adults with n..:

Mullin, Rebecca L ; Golding, John F ; Smith, Rebecca...
SAGE Open Medicine. 6 (2018) - p. 205031211878686 , 2018

Link: https://doi.org/10.1177/..

12

Evaluation of quality of life in adults with neurofibromato..:

Ferner, Rosalie E ; Thomas, Mary ; Mercer, Gemma...
Health and Quality of Life Outcomes. 15 (2017) 1 - p. , 2017

Link: https://doi.org/10.1186/..

13

Toxicity profile of bevacizumab in the UK Neurofibromatosis..:

On behalf of the UK NF2 research group ; Morris, Katrina A. ; Golding, John F....
Journal of Neuro-Oncology. 131 (2016) 1 - p. 117-124 , 2016

Link: https://doi.org/10.1007/..

14

Bevacizumab in neurofibromatosis type 2 (NF2) related vesti..:

Morris, Katrina A. ; Golding, John F. ; Axon, Patrick R....
Neuro-Oncology Practice. 3 (2016) 4 - p. 281-289 , 2016

Link: https://doi.org/10.1093/..

15

Intratympanic methylprednisolone versus gentamicin in patie..:

Patel, Mitesh ; Agarwal, Kiran ; Arshad, Qadeer...
The Lancet. 388 (2016) 10061 - p. 2753-2762 , 2016

Link: https://doi.org/10.1016/..